Bonsity FDA Approval History
Last updated by Judith Stewart, BPharm on July 6, 2021.
FDA Approved: Yes (First approved October 4, 2019)
Brand name: Bonsity
Generic name: teriparatide
Dosage form: Injection
Previous Name: PF708
Company: Pfenex Inc.
Treatment for: Osteoporosis
Bonsity (teriparatide) is a parathyroid hormone analog (PTH 1-34) indicated for the treatment of osteoporosis in certain patients at high risk for fracture.
Bonsity is approved in the U.S. under the 505(b)(2) regulatory pathway, with Forteo® (teriparatide injection) as the reference drug.
Bonsity is indicated for:
- Treatment of postmenopausal women with osteoporosis at high risk for fracture
- Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture
- Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture.
Development timeline for Bonsity
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
